2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Ernst M, Navani V, Wells J, Bakouny Z, Donskov F, Basappa N, Wood L, Meza L, Pal S, Szabados B, Powles T, Beuselinck B, McKay R, Lee J, Ernst D, Kapoor A, Yuasa T, Choueiri T, Heng D. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2023, 7: 501-508. PMID: 37914579, DOI: 10.1016/j.euo.2023.10.002.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaInternational mRCC Database ConsortiumCytoreductive nephrectomySystemic therapy initiationMetastatic kidney cancerRenal cell carcinomaCombination immunotherapyDeferred CNUpfront CNCN statusPrimary tumorOverall survivalTherapy initiationCell carcinomaInternational Metastatic Renal Cell Carcinoma Database ConsortiumAdvent of novel therapeutic agentsKidney cancerInitiation of systemic therapyDiagnosis of metastatic diseaseTreatment of choiceProportion of patientsCox proportional-hazards regressionCharacterization of patientsIO-based combinationsProportional-hazards regression
2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Loo Gan C, Huang J, Pan E, Xie W, Schmidt A, Labaki C, Meza L, Bouchard G, Li H, Jackson-Spence F, Sánchez-Ruiz C, Powles T, Kumar S, Weise N, Hall W, Rose B, Beuselinck B, Suarez C, Pal S, Choueiri T, Heng D, McKay R. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2022, 6: 204-211. PMID: 36328934, DOI: 10.1016/j.euo.2022.10.004.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaMRCC treated with cabozantinibRenal cell carcinomaAdverse eventsRisk-benefit assessmentCell carcinomaReceiving radiotherapyInternational Metastatic Renal Cell Carcinoma Database ConsortiumPatients treated with stereotactic ablative body radiotherapyInternational multicenter retrospective studyStereotactic ablative body radiotherapyPractice patternsConventional palliative radiotherapyGrade 5 eventsIntermediate-risk diseaseReceipt of radiotherapyMultiple brain metastasesMetastatic kidney cancerRadiotherapy-related toxicityCourse of radiotherapyEfficacy of cabozantinibMulticenter retrospective studyStudy of patientsOptimize treatment outcomesAssessment of patients